BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

Haematologica. 2018 Jan;103(1):e10-e12. doi: 10.3324/haematol.2017.176347. Epub 2017 Oct 5.

Authors

Konstantin Byrgazov¹, Chantal Blanche Lucini¹, Peter Valent², Oliver Hantschel³, Thomas Lion⁴

Affiliations

¹ Children's Cancer Research Institute; Vienna, Austria.
² Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, and Ludwig Boltzman Cluster Oncology, Vienna, Austria.
³ Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Switzerland.
⁴ Children's Cancer Research Institute, and Department of Pediatrics, Medical University of Vienna, Austria thomas.lion@ccri.at.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Alleles
Amino Acid Substitution
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm / genetics
Fusion Proteins, bcr-abl / genetics*
Gene Expression
Humans
Imidazoles / pharmacology*
Imidazoles / therapeutic use
Mutation*
Pharmacogenomic Testing
Pharmacogenomic Variants*
Protein Kinase Inhibitors / pharmacology*
Protein Kinase Inhibitors / therapeutic use
Pyridazines / pharmacology*
Pyridazines / therapeutic use

Substances

Antineoplastic Agents
BCR-ABL1 fusion protein, human
Imidazoles
Protein Kinase Inhibitors
Pyridazines
ponatinib
Fusion Proteins, bcr-abl